, Volume 23, Issue 2, pp 103–106 | Cite as

Pefloxacin versus chloramphenicol in the therapy of typhoid fever

  • P. Cristiano
  • M. R. Iovene
  • C. Imperatore
  • L. Imparato
  • P. Maio
  • C. Carpinelli
  • M. F. Corrado
  • F. Lauria


An open, randomized clinical study was carried out to compare the clinical efficacy and safety of pefloxacin with that of chloramphenicol in the treatment of typhoid fever. Sixty hospitalized patients (40 men and 20 women, aged from 17 to 64 years), affected by severe proven typhoid sepsis, were randomly assigned to treatment with pefloxacin at a daily dose of 1,200 mg for 15 days (Group A) or with chloramphenicol at a daily dose of 2 g for 15 days (Group B). The two groups of patients were statistically homogeneous regarding both age and sex and all patients were followed for 30 days after the end of therapy. In Group A all the patients completely recovered from infection and all the isolated strains ofSalmonella typhi were eradicated by pefloxacin treatment. In Group B two patients had a relapse, two patients became chronic enteric carriers ofS. typhi and only 26 patients recovered from infection with complete eradication of the pathogen. The results indicate that pefloxacin is as active as chloramphenicol in the therapy of typhoid fever and that pefloxacin could be a valid antibacterial agent to be used together with appropriate hygienic measures for an eradication program of typhoid fever in the endemic countries.


Clinical Study Infectious Disease General Practice Family Medicine Chloramphenicol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Pefloxacin im Vergleich zu Chloramphenicol bei Typhus


Zum Vergleich der klinischen Wirksamkeit und Sicherheit einer Behandlung mit Pefloxacin und Chloramphenicol in der Therapie des Typhus wurde eine offene, randomisierte klinische Studie durchgeführt. 60 hospitalisierte Patienten (40 Männer, 20 Frauen im Alter von 17 bis 64 Jahren) mit schwerem septischen Typhus erhielten nach Randomplan eine Behandlung mit Pefloxacin in einer Tagesdosis von 1.200 mg für 15 Tage (Gruppe A) oder mit Chloramphenicol in einer Tagesdosis von 2 g für 15 Tage (Gruppe B). Die beiden Patientengruppen waren hinsichtlich Alter und Geschlecht homogen, und alle Patienten wurden bis 30 Tage nach Therapieende nachkontrolliert. In der Gruppe A erholten sich alle Patienten vollständig von der Infektion. Alle isolierten Stämme vonSalmonella typhi waren nach Behandlung mit Pefloxacin eradiziert. In der Gruppe B traten bei zwei Patienten Rezidive auf, zwei Patienten wurden chronische Träger vonS. typhi und nur 26 Patienten waren nach der Erholung vollständig erregerfrei. Die Ergebnisse zeigten, daß Pefloxacin ebenso aktiv wie Chloramphenicol in der Behandlung des Typhus ist und ein wertvolles Antibiotikum darstellt, das zusammen mit Hygienemaßnahmen eingesetzt werden kann, um in den endemischen Ländern ein Eradikationsprogramm für Typhus durchzuführen.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hook, W. Salmonella species (including typhoid fever). In:Mandell, G. L., Douglas, R. G. J., Bennett, J. E. (eds.): Principles and practice of infectious diseases. Churchill Livingstone, Inc., New York 1990, pp. 1700–1716.Google Scholar
  2. 2.
    Trujillo, Z., Quiroz, C., Gutierrez, M. A., Arias, J., Renteria, M. Fluoroquinolones in the treatment of typhoid fever and the carrier state. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 334–341.PubMedGoogle Scholar
  3. 3.
    Brouqui, P., Rault, D.: Fièvre typhoide — Editions Techniques — Encycl. Méd. Chir. — Maladies Infectieuses, F.r. 8-019-A-10, 1re ed., Paris 1992, p. 4.Google Scholar
  4. 4.
    Butler, T., Linh, N. N., Arnold, K., Pollack, M. Chloramphenicol-resistant typhoid fever in Vietnam associated with R factor. Lancet ii (1973) 983–985.Google Scholar
  5. 5.
    OMS Pharmacorésistance transférable chez les Salmonelles en Amérique Centrale et en Amérique du Sud. Relève Epidem. Hebdomadaire 8 (1974) 65–69.Google Scholar
  6. 6.
    Paniker, C. K. J., Vimola, K. N. Transferable chloramphenicol resistance inSalmonella typhi. Nature 239 (1972) 109–110.PubMedGoogle Scholar
  7. 7.
    Samantaray, S. K. Typhoid fever resistant to furazolidone, ampicillin, chloramphenicol, and co-trimoxazole. Indian J. Med. Sci. 33 (1979) 1–3.PubMedGoogle Scholar
  8. 8.
    Datta, N., Richards, H., Datta, C. Salmonella typhi in vivo acquires resistance to both chloramphenicol and cotrimoxazole. Lancet i (1981) 1181–1183.Google Scholar
  9. 9.
    Verbist, L. In vitro activity of pefloxacin against microorganisms multiply resistant to β-lactam antibiotics and aminoglycosides. J. Antimicrob. Chemother. 17 (Suppl. B) (1986) 11–17.Google Scholar
  10. 10.
    Yourassowsky, E., Van der Linden, M. P., Crokaert, F., Glupczynshi, J. In vitro activity of pefloxacin compared to other antibiotics. J. Antimicrob. Chemother. 17 (Suppl. B) (1986) 19–28.Google Scholar
  11. 11.
    Montay, J., Goueffon, Y., Roquet, F. Absorption, distribution, metabolic fate and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys and humans. J. Antimicrob. Chemother. 25 (1984) 463–472.Google Scholar
  12. 12.
    Pangon, B., Gehanno, P., Daldoss, C., Legrand, P.: Tissue diffusion of pefloxacin: study in man. Proceedings 13th Int. Congr. Chemother. Vienna 1983, pp. 110/29–110/30.Google Scholar
  13. 13.
    Fourtillan, J. B. Comportement pharmacocinétique de la péfloxacine chez l'homme. Revue Méd. Interne 7 (1986) 185–195.Google Scholar
  14. 14.
    Carlier, M. B., Scorneaux, B., Zenebergh, A., Desnottes, J. F., Tulkens, P. M. Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages. J. Antimicrob. Chemother. 26 (Suppl. B) (1990) 27–39.PubMedGoogle Scholar
  15. 15.
    Hajji, M., El Mdaghri, N., Benbachir, M., Marhoum El Filali, K., Himmich, H. Prospective randomized comparative trial of pefloxacin versus cotrimoxazole in the treatment of typhoid fever in adults. Eur. J. Clin. Microbiol. Infect. Dis. 7 (1988) 361–363.PubMedGoogle Scholar
  16. 16.
    Cristiano, P., Morelli, G., Briante, V., Iovene, M. R., Simioli, F., Altucci, P. Clinical experience with pefloxacin in the therapy of typhoid fever. Infection 17 (1989) 86–87.PubMedGoogle Scholar
  17. 17.
    Bauer, A. W., Kirby, W. M., Sherris, J. C., Turck, M. Antibiotic susceptibility testing by a standardized single disc method. Am. J. Clin. Pathol. 45 (1966) 493–496.PubMedGoogle Scholar
  18. 18.
    Ericsson, H. M., Sherris, J. C. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol. Microbiol. Scand. 217 (Suppl. 1) (1971) 1–90.Google Scholar
  19. 19.
    Morelli, G., Mazzoli, S., Tortoli, E., Simonetti, M. T., Perruna, F., Postiglione, A. Fluoroquinolones versus chloramphenicol in the therapy of typhoid fever: a clinical and microbiological study. Current Ther. Research 52 (1992) 532–542.Google Scholar

Copyright information

© MMV Medizin Verlag GmbH 1995

Authors and Affiliations

  • P. Cristiano
    • 1
  • M. R. Iovene
    • 1
  • C. Imperatore
    • 1
  • L. Imparato
    • 2
  • P. Maio
    • 2
  • C. Carpinelli
    • 3
  • M. F. Corrado
    • 3
  • F. Lauria
    • 4
  1. 1.Dipartimento di Internistica Clinica e Sperimentale “F. Magrassi”, IV Clinica Medica GeneraleNuovo Policlinico di NapoliNapoli
  2. 2.Dept. of Infectious DiseasesHospital “San G. Moscati”, (USL 4)Avellino
  3. 3.Dept. of Infectious DiseasesHospital “Villa Malta”, (USL 52)Sarno (SA)
  4. 4.Dept. of Infectious DiseasesUnited Hospitals of “Vallo di Diano”, (USL 57)Polla (SA)Italy

Personalised recommendations